6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema

6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema

Hemodynamic Classification & Pathophysiology

Acute decompensated heart failure (ADHF) is characterized by acute elevations in left ventricular end-diastolic pressure (LVEDP) and pulmonary capillary wedge pressure (PCWP >18 mmHg), resulting in alveolar fluid transudation, severe hypoxemia, and secondary neurohormonal activation. Clinical evaluation in the emergency department centers on the Forrester Hemodynamic Subsets, classifying patients across two physiological axes: Congestion (volume status / PCWP) and Perfusion (cardiac output / Cardiac Index [CI]):

                       FORRESTER HEMODYNAMIC MATRIX
                      
                              CONGESTION (PCWP)
                       Dry (PCWP ≤18)     Wet (PCWP >18)
                     ┌──────────────────┬──────────────────┐
       Warm          │    SUBSET I      │    SUBSET II     │
  (CI ≥2.2 L/min/m²) │   Warm & Dry     │   Warm & Wet     │
                     │  (Compensated)   │ (Most Common, 80%)│
   PERFUSION         ├──────────────────┼──────────────────┤
       Cold          │   SUBSET III     │    SUBSET IV     │
  (CI <2.2 L/min/m²) │   Cold & Dry     │   Cold & Wet     │
                     │ (Hypovolemia/Low)│(Cardiogenic Shock)│
                     └──────────────────┴──────────────────┘

Clinical Profiling & Targeted Interventions

1. Subset I: Warm & Dry (Compensated):

   • Hemodynamics: CI ≥2.2 L/min/m², PCWP ≤18 mmHg.
   • Clinical Features: Adequate systemic perfusion, no orthopnea, clear lungs, no jugular venous distension (JVD) or peripheral edema.
   • Management: Continue and optimize outpatient oral guideline-directed medical therapy (GDMT).

2. Subset II: Warm & Wet (Congested, Adequately Perfused):

   • Hemodynamics: CI ≥2.2 L/min/m², PCWP >18 mmHg.
   • Clinical Features: Represents approximately 80% of emergency department presentations. Warm extremities, brisk capillary refill, bounding pulses, accompanied by orthopnea, paroxysmal nocturnal dyspnea, elevated JVD, pulmonary rales, and lower extremity edema.
   • Management: Intravenous loop diuretics combined with intravenous vasodilators (nitroglycerin or sodium nitroprusside).

3. Subset III: Cold & Dry (Hypoperfused, Non-Congested):

   • Hemodynamics: CI <2.2 L/min/m², PCWP ≤18 mmHg.
   • Clinical Features: Cool, pale extremities, narrow pulse pressure, delayed capillary refill, worsening renal function (prerenal azotemia), without pulmonary rales, hepatomegaly, or peripheral edema. Often reflects aggressive overdiuresis or relative hypovolemia.
   • Management: Cautious volume challenge (250 to 500 mL crystalloid bolus). If filling pressures rise without cardiac output improvement, initiate inotropes (dobutamine or milrinone).

4. Subset IV: Cold & Wet (Cardiogenic Shock):

   • Hemodynamics: CI <2.2 L/min/m², PCWP >18 mmHg.
   • Clinical Features: Markedly compromised end-organ perfusion (oliguria, altered mentation, cool mottled extremities, systemic lactic acidosis) alongside florid pulmonary edema and severe systemic congestion.
   • Management: Inotropic support (dobutamine or milrinone) to enhance forward flow, vasopressor therapy (norepinephrine as first-line if MAP <65 mmHg), mechanical circulatory support (intra-aortic balloon pump, percutaneous ventricular assist device), and judicious decongestion once mean arterial pressure is restored.

---

Loop Diuretic Strategies & The DOSE Trial

Loop diuretics remain the cornerstone of decongestive pharmacotherapy. They inhibit the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, promoting marked excretion of sodium, chloride, and water.

Dosing Equivalencies & Pharmacokinetics

• Oral to Intravenous Bioavailability:
  • Oral furosemide exhibits erratic bioavailability (~50%, ranging from 10% to 90%), which is further blunted by intestinal mucosal edema in acute decompensation. Thus, the oral-to-intravenous conversion ratio is 2:1 (40 mg PO furosemide = 20 mg IV furosemide).
  • Torsemide (~80% to 100%) and bumetanide (~80% to 100%) exhibit predictable, high oral bioavailability.
• Potency Equivalencies:
  • Bumetanide 1 mg IV/PO = Torsemide 20 mg PO = Furosemide 40 mg PO = Furosemide 20 mg IV.

The Landmark DOSE Trial

The Diuretic Optimization Strategies Evaluation (DOSE) trial evaluated acute loop diuretic strategies in patients hospitalized with ADHF across two randomized dimensions:

1. High-Dose vs Low-Dose:
   • High-Dose Strategy: Administered 2.5 times the patient's home daily oral loop diuretic dose in intravenous equivalents.
   • Low-Dose Strategy: Administered 1.0 times the home oral daily dose in IV equivalents.
   • Outcome: The high-dose strategy achieved significantly greater net fluid loss, greater weight reduction, and faster relief of dyspnea without difference in hospital length of stay. While transient worsening of renal function (defined as serum creatinine rise >0.3 mg/dL) was observed slightly more often in the high-dose cohort at 72 hours, this resolved completely by day 60 and did not predict worse long-term outcomes.
2. Continuous Infusion vs Intermittent Boluses:
   • Continuous infusion (with a loading bolus) vs intermittent boluses administered every 12 hours showed no statistically significant differences in global symptom relief or renal function preservation. Either modality is clinically acceptable; intermittent boluses are favored in the emergency department for operational simplicity.

For loop diuretic-naive patients presenting with ADHF, the recommended starting regimen is furosemide 20 to 40 mg IV or bumetanide 0.5 to 1 mg IV.

---

Overcoming Diuretic Resistance: Sequential Nephron Blockade

Chronic loop diuretic exposure leads to compensatory structural hypertrophy and functional hyperplasia of distal convoluted tubule and collecting duct epithelial cells. This "braking phenomenon" drastically increases distal sodium reabsorption via the thiazide-sensitive Na⁺/Cl⁻ cotransporter (NCC) and epithelial sodium channels (ENaC), neutralizing loop diuretic efficacy.

                       SEQUENTIAL NEPHRON BLOCKADE
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ 1. Proximal Convoluted Tubule: Acetazolamide (500 mg IV daily)            │
  │    - Carbonic anhydrase inhibition (ADVOR Trial)                          │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ 2. Thick Ascending Limb of Henle: Loop Diuretics (Furosemide / Bumetanide)│
  │    - Na+/K+/2Cl- cotransporter inhibition (DOSE Trial)                    │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ 3. Distal Convoluted Tubule: Thiazide Diuretics (Metolazone / Chloroth.) │
  │    - Na+/Cl- cotransporter inhibition (Blocks distal compensation)        │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ 4. Cortical Collecting Duct: Mineralocorticoid Antagonists (Spironolactone)│
  │    - Aldosterone receptor blockade (Long-term neurohormonal remodeling)   │
  └───────────────────────────────────────────────────────────────────────────┘

Sequential Nephron Blockade Formulary

1. Oral Metolazone:
   • Dosing: 2.5 to 5 mg orally once daily (maximum 10 mg), administered 30 to 60 minutes prior to the intravenous loop diuretic dose.
   • Pharmacology: Quinazoline thiazide-like diuretic that selectively inhibits the Na⁺/Cl⁻ cotransporter in the cortical diluting segment. Features an extended elimination half-life (20 to 24 hours) and maintains potent natriuretic activity even in severe renal impairment with glomerular filtration rates <30 mL/min.
2. Intravenous Chlorothiazide:
   • Dosing: 500 to 1,000 mg IV every 12 to 24 hours.
   • Pharmacology: Parenteral thiazide diuretic. Indicated when significant bowel wall edema, gastroparesis, or vomiting impedes the absorption of enteral metolazone.
3. Intravenous Acetazolamide (The ADVOR Trial):
   • Dosing: 500 mg IV once daily.
   • Pharmacology: Carbonic anhydrase inhibitor acting on the proximal convoluted tubule, blocking upstream sodium and bicarbonate reabsorption. The landmark ADVOR trial (2022) demonstrated that adding IV acetazolamide to standardized high-dose IV loop diuretics resulted in a significantly higher proportion of patients achieving complete decongestion within 3 days (42.2% vs 30.5%; p <0.001) without worsening renal endpoints or causing hypokalemia.

---

Vasodilator Therapy in Cardiogenic Pulmonary Edema & SCAPE

Sympathetic Crashing Acute Pulmonary Edema (SCAPE)

SCAPE is an acute, hyperadrenergic emergency characterized by abrupt sympathetic surge, massive systemic vasoconstriction, profound afterload mismatch, and rapid redistribution of fluid from the systemic splanchnic circulation into the pulmonary capillary bed. Patients present in severe respiratory distress with hypertension (systolic BP often >180–200 mmHg), tachypnea, diffuse rales, and pink frothy secretions over minutes to hours. Importantly, these patients are often euvolemic or only mildly hypervolemic; the primary pathology is vascular redistribution rather than total-body fluid overload. Diuretics alone are too slow and ineffective; rapid, aggressive afterload reduction is life-saving.

High-Dose Intravenous Nitroglycerin

• Mechanism: Low-dose nitroglycerin (<100 mcg/min) primarily dilates capacitance veins, lowering preload. In contrast, high-dose nitroglycerin (>100 to 300+ mcg/min) induces potent systemic arteriolar dilation, lowering systemic vascular resistance, decreasing LV afterload and transmural pressure, and abruptly halting transudation into the alveoli.
• Administration Protocol: Initiate at 50 to 100 mcg/min and titrate aggressively by 50 to 100 mcg/min every 3 to 5 minutes targeting symptomatic relief and BP control. Alternatively, administer immediate IV pushes of 1 to 2 mg over 1 to 2 minutes followed by a continuous infusion at 100 mcg/min.

Sodium Nitroprusside

• Mechanism: Balanced direct nitric oxide donor providing simultaneous arterial and venous vasodilation. Drastically reduces both cardiac preload and afterload.
• Dosing: Continuous IV infusion initiated at 0.5 to 3 mcg/kg/min.
• Monitoring & Cyanide/Thiocyanate Toxicity:
  • Requires continuous invasive intra-arterial blood pressure monitoring due to potency and risk of precipitous hypotension.
  • Nitroprusside metabolism produces cyanide ions, which are converted by hepatic rhodanase into thiocyanate and cleared renally.
  • Toxicity Risk: Doses >3 mcg/kg/min, prolonged infusions (>48 hours), or renal/hepatic impairment result in cyanide toxicity (manifesting as severe lactic acidosis, altered mental status, and cardiovascular collapse) or thiocyanate toxicity (tinnitus, delirium, hyperreflexia, seizures). Co-infusion of sodium thiosulfate or treatment with hydroxocobalamin is indicated for cyanide toxicity.

Non-Invasive Positive Pressure Ventilation (NIPPV) Synergy

Non-invasive ventilation (CPAP 5 to 10 cm H2O or BiPAP with IPAP 10 to 15 / EPAP 5 cm H2O) operates synergistically with vasodilators:

1. Increases intrathoracic pressure, thereby decreasing right ventricular venous return (reducing preload).
2. Decreases left ventricular transmural pressure (reducing afterload).
3. Recruits fluid-filled, atelectatic alveoli and drives fluid back into the pulmonary interstitial space, rapidly improving PaO2/FiO2 ratios, reducing work of breathing, and averting endotracheal intubation.

---

Medication Safety: Drugs to Avoid in ADHF

Certain common pharmacotherapies exacerbate myocardial failure and are strictly contraindicated during acute decompensation: